3.02
+0.13(+4.50%)
Currency In USD
| Previous Close | 2.89 |
| Open | 2.9 |
| Day High | 3.03 |
| Day Low | 2.85 |
| 52-Week High | 11.46 |
| 52-Week Low | 1.07 |
| Volume | 2.82M |
| Average Volume | 6.74M |
| Market Cap | 280.04M |
| PE | -3.21 |
| EPS | -0.94 |
| Moving Average 50 Days | 5.92 |
| Moving Average 200 Days | 5.91 |
| Change | 0.13 |
If you invested $1000 in Rezolute, Inc. (RZLT) 10 years ago, it would be worth $46.46 as of January 22, 2026 at a share price of $3.02. Whereas If you bought $1000 worth of Rezolute, Inc. (RZLT) shares 5 years ago, it would be worth $198.29 as of January 22, 2026 at a share price of $3.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today at 8:30am ET REDWOOD CITY, Ca
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
GlobeNewswire Inc.
Nov 05, 2025 12:30 PM GMT
Webcast scheduled for Monday, November 10 at 12:00 pm ESTREDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused